



Application of Machine Learning for Early Disease Diagnosis in Healthcare

Sabit Md Asad¹, Md Ahabab Hussain², Raiyan Muntasir Monim³, Kamrul Islam⁴*

¹School of Mechanical and Mechatronics Engineering, Kyung Sung University, Busan, South Korea

²College of Commerce and Economics, Kyung Sung University, Busan, South Korea

³Department of Computer Science of Engineering, Ahsanullah University of Science & Technology, Dhaka, Bangladesh

⁴College of Commerce and Economics, Kyung Sung University, Busan, South Korea

*Corresponding Author E-mail: Kamrulislam01685@kyung Sung.ac.kr

Abstract: Machine Learning (ML) is transforming the healthcare field by allowing early detection of diseases with unprecedented accuracy and efficiency by utilizing a variety of data types, including medical imaging, genetic sequences, electronic health records, and physiological data to identify subtle trends and determine the presence of diseases. This paper gives an extensive overview of the application of ML in early detection of critical conditions such as diabetes, cancer, cardiovascular disease, Alzheimer's disease, and sepsis. We explain the entire process, encompassing data collection and preprocessing, model training and validation, and the eventual implementation into a clinical setting. Other models, like convolutional neural networks in radiological image classification and recurrent neural networks in time-series pattern recognition, continue to perform better in terms of sensitivity and specificity than conventional diagnostic techniques. Experiments on the four innovative architectures, including CNN+LSTM Hybrid with an AUC of 0.93, XGBoost+DNN Ensemble at 0.91, Vision Transformer achieving 0.96, and Federated Learning at 0.89, demonstrate their excellent performance as a diagnostic tool. The Vision Transformer is superior in cardiovascular disease (0.976) and diabetes (0.970), whereas Federated Learning dominates in sepsis detection (0.878), recognizing the importance of privacy. Other notable contributions are a comparative paper on model performance and computational efficiency, where training time ranged between 14.2 and 22.8 hours, the application of ethical frameworks addressing bias mitigation and interpretability, but also a real-world validation that showed up to 18 percent performance degradation in community setting environments, informing how to scale deployment. ML holds the potential of an active, personalized, proactive healthcare system lessening diagnostic errors and disparities, yet necessitates interdisciplinary cooperation to mitigate bias, transparency, and regulatory implications yielding equitable, effective clinical integration to global health overall better outcomes.

Keywords: Early Disease Diagnosis, Medical Imaging, Predictive Analysis, Machine Learning, Algorithmic Bias.

Introduction

Machine learning (ML) is at the vanguard of the extraordinary integration of cutting-edge technology that has characterized the rapid progress of healthcare in the twenty-first century [1]. Large datasets and complex algorithms are used in machine learning, a subfield of artificial intelligence, to identify trends, predict results, and automate decision-making procedures that previously only used human judgment [2]. Machine learning (ML) has become a potent instrument in the field of disease diagnosis, with the potential to completely transform the way illnesses are identified, diagnosed, and treated, particularly in their early stages, when intervention can be most successful [3]. Despite being the cornerstone of clinical practice,



traditional diagnostic techniques are frequently constrained by human subjectivity, time restraints, and the overwhelming amount and complexity of contemporary medical data [4]. To diagnose illnesses, doctors use their expertise, gut feelings, and the diagnostic tests that are currently available [5]. However, when dealing with uncommon or complicated conditions, it is simple to overlook small trends or early warning indicators. Machine learning addresses these limitations by evaluating large amounts of heterogeneous data, including genetic information, laboratory results, medical images, and electronic health records, at speeds and precision that are not possible with manual analysis. This ability not only improves professionals' diagnostic skills but also opens the door to earlier and more accurate illness identification [6].

One of the most important applications of machine learning in healthcare is the early diagnosis of diseases, including COVID-19, cancer, heart disease, diabetes, and Alzheimer's disease [7]. In radiology, for example, machine learning models trained on thousands of annotated pictures are able to detect minuscule abnormalities in MRIs, CT scans, or X-rays, like cancers or lesions, with surprising accuracy, frequently outperforming human performance in terms of sensitivity and specificity [8]. Machine learning algorithms are used in cardiology to examine electrocardiograms (ECGs) and other physiological signals in order to identify arrhythmias or anticipate cardiac events before they manifest clinically [9]. Similarly, by examining minute alterations in brain imaging or patient behavior, machine learning approaches have shown excellent accuracy in neurology in differentiating between early-stage Alzheimer's disease and normal cognitive aging [10]. Beyond imagination, ML is excellent at combining many data sources to evaluate illness risk and forecast onset. ML models can stratify people based on their risk of getting particular disorders by examining patient demographics, lifestyle factors, genetic predispositions, and past medical records [11]. By implementing focused screening programs, starting preventative treatments, and customizing treatment plans, healthcare professionals can use this predictive power to move the emphasis from reactive care to proactive health management. This strategy can greatly improve results and lower long-term healthcare expenditures in chronic conditions like diabetes or heart disease where early intervention is crucial [12].

Beyond clinical accuracy, machine learning offers advantages in early illness diagnosis. By optimizing processes, cutting down on pointless testing, and lowering diagnostic mistakes, ML-driven systems improve operational efficiency [7]. Healthcare workers can concentrate on sophisticated decision-making and patient care by using automated medical data analysis to free up crucial clinician time. Additionally, because ML solutions are scalable, high-quality diagnostic assistance can be provided in settings with limited resources or marginalized populations, thus lowering inequities in healthcare outcomes and access [13]. The application of machine learning to disease diagnosis is not without difficulties, despite its potential. To guarantee the fair and moral application of ML technology, concerns including data privacy, security, algorithmic transparency, and potential biases in training data must be addressed [14]. To create reliable, understandable, and clinically verified models that can be securely incorporated into healthcare systems, data scientists, physicians, and regulatory agencies must work together. Additionally, ongoing research aims to make ML algorithms more interpretable so that physicians can comprehend and have confidence in the advice these systems produce [3].

Deep learning, a subfield of machine learning characterized by multi-layered neural networks, has seen recent advancements that have advanced the science and, in some applications, attained diagnostic accuracies of over 90% [15]. For example, convolutional neural networks (CNNs) have demonstrated impressive performance in image-based diagnostics, while



recurrent neural networks (RNNs) and other designs are being explored for time-series data and natural language processing applications in the healthcare industry [16]. In addition to these technological developments, a growing number of high-quality medical datasets are becoming accessible, which is essential for developing and assessing trustworthy machine learning models. Around the world, research and pilot clinical settings are already demonstrating the revolutionary potential of machine learning for early disease diagnosis [17]. It is anticipated that as the technology advances, its uptake will quicken, propelling a change in healthcare toward more accurate, effective, and patient-centered treatment. In addition to improving the results for individual patients, early disease detection has significant public health consequences since it allows for earlier therapies, lessens the burden of advanced disease, and optimizes resource allocation across healthcare systems [18].

This study aims to thoroughly examine and evaluate the application of machine learning techniques for early disease diagnosis in the medical field in order to identify current capabilities, challenges, and possible future advancements. This paper aims to provide a comprehensive understanding of how machine learning (ML) can be utilized to enhance patient outcomes, improve diagnostic accuracy, and facilitate predictive, preventive, and personalized medicine by integrating recent developments, case studies, and emerging trends. Ultimately, the study aims to educate stakeholders, including physicians, data scientists, legislators, and patients, about the revolutionary potential of machine learning in early disease detection, while highlighting the key factors necessary for its responsible and successful implementation in real-world healthcare settings.

The novelty of the study is the integration of hybrid ML architectures, in which convolutional and recurrent neural networks have been used along with ensemble methods, as well as the application of federated learning as a privacy-preserving method of multi-institution model training. This method will provide reliable diagnostics on heterogeneous data without a loss of data security, which was a critical shortcoming of scalable and ethical use of ML in medical practice.

The contribution of this study can be put as:

- The comparative analysis between four ML architectures involved measurement of respective performance metrics in addition to their computing efficiencies (14.2 hours to 22.8 hours training times).
- The elaboration of ethical models of bias reduction and explanation of the model and the strengthening of the trust of clinicians and regulatory bodies.
- Field-testing and up to 18% performance degradation in community environments, supplying knowledge toward practical clinical use.
- Development of federated learning that would have allowed the institutions to collaborate in diagnostics without compromising the privacy of their patients.

Background Study

Machine learning and artificial intelligence have significantly improved the capacity to anticipate and detect health problems. Their use is accelerating, despite some skepticism about their practical application in healthcare. In fields including neuroimaging, genetics, radiography, and electronic health records, methods like supervised, unsupervised, and reinforcement learning are being used. However, difficulties including privacy threats and moral dilemmas still pose problems. Future applications should consider these challenges and provide suggestions for improvement [19]. By enhancing early diagnosis and optimizing



processes, developments in machine learning and predictive analytics are revolutionizing the healthcare industry. Prompt intervention for chronic disorders, including diabetes, cardiovascular disease, and cancer, is made possible by these technologies' ability to process enormous datasets and determine the risk of disease development before clinical signs appear. Furthermore, healthcare institutions can improve overall management by more effectively allocating people and resources thanks to their predictive power [20]. The application of machine learning to artificial intelligence systems for disease early detection and healthcare model forecasting based on diagnoses was examined in one study. There are many advantages to early sickness detection and healthcare process optimization. But there are still significant obstacles to overcome, such as safeguarding patient data, maintaining security, reducing algorithmic bias, and establishing system interoperability. The performance of machine learning models is expected to be substantially strengthened by technological advancements, especially in fields like deep learning and natural language processing. Collaborative healthcare networks can improve communication and provide more integrated treatment by leveraging predictive analytics [21].

ML applications are revolutionizing healthcare by improving the speed and accuracy of physicians' work. AI technology can help address the shortage of skilled physicians and improve data collection and analysis. By examining satellite imagery, news articles, social media posts, and video information, machine learning techniques can detect early indicators of pandemics or epidemics. Healthcare workers now have additional options thanks to this development, which frees them up to focus more on patient care rather than information gathering [22]. Machine learning-powered solutions improve hospital operations, lower healthcare costs, and provide customized therapies and alternate treatment options. By developing clinical decision support systems, enhancing illness detection, and customizing treatment regimens, machine learning is poised to have a significant impact on physicians and healthcare organizations, ultimately leading to better patient outcomes [23]. Machine learning has garnered a lot of attention in the last 10 years due to its capacity to effectively store, process, and analyze enormous volumes of data. In order to find hidden patterns and relationships in data, advanced algorithms are being used more and more. This helps firms make better decisions and maximize important performance indicators [24]. Machine learning algorithms can be used in a variety of fields because they are domain-independent. One study looked at two particular uses for automated medical data interpretation: using artificial neural networks for automated cell image classification to determine the severity and progression of breast cancer, and using Bayesian Inference to diagnose Alzheimer's disease based on cognitive tests and demographic data. The efficiency of machine learning techniques in providing quick, effective, and automated data analysis was highlighted in the study [25].

Advancements in machine learning and big data have opened up opportunities in healthcare, enabling precise disease diagnosis, innovative treatment methods, remote monitoring, drug discovery, and cost reduction. Even though it can be computationally taxing to apply machine intelligence algorithms to large amounts of healthcare data, recent advancements in technology have made its use more viable [26]. A recent study explored the use of machine learning to healthcare datasets, focusing on topics including risk assessment, disease diagnosis, health monitoring, medical advancements, and epidemic outbreak prediction. The objective was to promote further research in this area and provide a comprehensive overview of machine learning applications in healthcare [27]. Machine learning plays a crucial role in the healthcare industry for disease detection and management. It reduces the number of false positives and speeds up decision-making. Disease identification and diagnosis have been significantly impacted by recent developments in machine learning techniques, including Support Vector Machines (SVM), K-Nearest Neighbors (KNN), Naive Bayes, and Decision Trees. These



techniques are used to diagnose diseases like diabetes, cancer, epilepsy, and heart attacks. A mathematical basis for assessing machine learning algorithms utilizing metrics such as accuracy, precision, recall, and the F1 score was also provided by another study [28].

In the healthcare industry, machine learning (ML) algorithms have been crucial in predicting illnesses and facilitating early detection. However, questions about their accuracy and dependability still exist. Some algorithms may have trouble when used on certain datasets, even while they work well on others. The development of portable gadgets for disease detection and treatment consultation is becoming more and more important as telemedicine gains traction [29]. DNA sequences, oxygen content, and heart rhythm are just a few of the data kinds that are subjected to machine learning algorithms. Disease detection also requires visual recognition. Because recurrent neural networks can forecast future values from data sequences, they are recommended [30]. Comparative analysis is essential for domain adaptation because machine learning algorithms rely on data. An improved strategy is required to make ML algorithms more resilient because they can be tricked by adversarial attacks. When feature extraction algorithms offer superior virtual data for classification, certain machine learning algorithms perform at their peak efficiency [31]. Still, there are questions regarding the algorithms' forecasts. To solve these problems, a comparative study of every ML algorithm is required. Compared to traditional machine learning, which depends on accuracy loss, the proposed model with a better methodology achieves improved accuracy and confidence. To build trust in the models' dependability, the method was evaluated using ensemble learning on the Pima Indian diabetes dataset (PIDD) and breast cancer [32].

Methodology

This study's methodology integrates data collection, algorithmic development, clinical validation, and ethical governance methodically to assess machine learning (ML) applications in early disease diagnosis [33], [34], [35], [36]. The organized workflow and essential elements are listed below:

Research flowchart

The study follows an end-to-end workflow, which includes:

- i. **Data acquisition:** Data acquisition is the process of gathering a variety of medical datasets from multiple sources, including genomic databases, wearable technology, imaging systems, and electronic health records (EHRs). These datasets frequently vary in format, scale, and structure, making them heterogeneous in nature. Harmonization techniques are necessary for aggregating such data in order to guarantee uniformity and compatibility throughout various healthcare platforms. The basis for trustworthy analysis and model construction is established by appropriate data collection.
- ii. **Preprocessing:** One crucial step in getting raw data ready for analysis is preprocessing. It provides normalization, which allows for fair feature comparison by scaling data to a standard range. Missing value imputation uses machine learning or statistical methods to deal with incomplete data entries. In order to improve model performance, feature engineering entails developing significant input variables that capture crucial patterns and relationships.
- iii. **Model development:** Model development is the process of choosing appropriate algorithms, like decision trees, support vector machines, or deep learning networks, that are suited to the problem domain. A hybrid architecture, which combines several



- models, is frequently intended to take advantage of each model's unique capabilities in order to increase accuracy and resilience.
- iv. **Validation:** Validation uses strict performance testing against predetermined requirements to guarantee the model's clinical utility. This comprises measures that are confirmed by separate test sets and cross-validation, such as sensitivity, specificity, and AUC-ROC.
 - v. **Deployment:** The model is included in clinical workflows through deployment. Safeguards for interpretability are emphasized in order to preserve openness, guarantee confidence, and assist physicians in making decisions.

And the overview of this study is depicted in Figure 1.




Figure 1: End-to-end workflow

Data collection

The paper made use of a range of sets of data sourced in various resources in order to achieve an ample scope in terms of disease types and clinical modality. There are three main categories of data sets which were included:

1. Public Repositories

Common benchmark datasets were also included such as those at the UCI Machine Learning Repository. Data examples are the Cleveland Heart Disease and PIMA Indian Diabetes databases that respectively record cardiovascular and metabolic diseases. The repositories offer standardized, structured clinical and Laboratory data that may be compared in a common manner across studies.

2. Medical Imaging Archives



Imaging data to identify disease-specific visual patterns were obtained based on existing resources in online databases like the NIH chest X-ray archive and the ISIC Skin Lesion database. All these collections feature mainly pneumonia and cancer subtypes, thus facilitating a multimodal approach in a variety of modalities, including radiological and dermatologic imaging.

3. EHR-derived Datasets

A real-world electronic health record (EHR) dataset was used and combined to reflect real-world multimorbidity profiles. Data sources were MIMIC-IV critical care database and anonymized patient data of institutional partners like St. Vincent Hospital. These records brought in great temporal, diagnostic and treatment histories to the study thus increasing its power with which the study could generalize to the practice.

A pre-structured definition of the datasets is shown in Table 1.

Table 1: Data sources

Dataset Type	Examples	Diseases Covered	Source
Public repositories	Cleveland Heart, PIMA Diabetes	Cardiovascular, Metabolic	UCI ML Repository 13
Medical imaging archives	NIH Chest X-rays, ISIC Skin Lesions	Pneumonia, Cancer	NIH/ISIC portals 3
EHR-derived datasets	MIMIC-IV, St. Vincent's Hospital	Multimorbidity	Institutional partners

Data preprocessing

There is a robust preprocess pipeline applied to the dataset to boost the model performance and generalizability. The steps are the following:

- **Handling missing values:** Laboratory data frequently had incomplete entries because of incomplete tests. In order to address this, median imputation was used. In terms of a feature, x_j , with missing values, the imputation value of a single missing entry is:

$$x_{i,j}^{imputed} = median(x_j), \quad \forall i \in \{missing\ indices\ of\ x_j\} \quad (1)$$

This technique is resistant to outliers in contrast to mean replacement, and extreme values can not bias the central tendency.

- **Normalization:** Min-max normalization was used to ensure the features of all vital signs were in a similar range and facilitate convergence of gradient-based models:

$$x_{i,j}^{imputed} = \frac{x_{i,j} - \min(x_j)}{\max(x_j) - \min(x_j)}, \quad \forall i, j \quad (2)$$

where $x_{i,j}$ is the original value of the j -th feature for the i -th sample. After scaling, all values lie in the range $[0,1]$.

- **Class balancing:** Due to the occurrences of rare illnesses in the data, the dataset was palpable through having class imbalances, which might bias the model towards some classes being majority during training. To create synthetic oversampled instances of minority classes, the Synthetic Minority Oversampling Technique (SMOTE) was applied. Given a minority class sample x_i and one of its closest neighbors x_i^{NN} , a synthetic sample is created based on:

$$x_{synthetic} = x_i + \lambda \cdot (x_i^{NN} - x_i), \lambda \sim (U(0,1)) \quad (3)$$



This method blends between available minority samples to fill out the samples and to neutralize the class distribution.

- **Feature selection:** SHapley Additive exPlanations (SHAP) values were calculated to highlight the most predictive elements. SHAP value ϕ_j quantifies how feature j contributes to the model prediction $f(x)$:

$$f(x) = \phi_0 + \sum_{j=1}^M \phi_j \quad (4)$$

where ϕ_0 is the expected model output and M is the total number of features. Features with higher absolute SHAP values were selected as the most influential predictors.

Model Development

To holistically test the predictive performance on ensemble methods across a range of modalities, 4 complementary approaches were formulated and applied, namely a hybrid deep learning model CNN+LSTM Hybrid, an ensemble method combining tree-based and neural components XGBoost+DNN, a self-attention-driven neural model Vision Transformer, and a privacy-preserving distributed paradigm Federated Learning. Their elaborate explanations, along with the mathematical representations are illustrated below.

1. CNN+LSTM Hybrid

The model combines convolutional layers in feature extraction tasks in space with recurrent layers in learning sequence tasks in the temporal domain. Given an input sequence of images or temporal medical measurements $\{x_t\}_{t=1}^T$ the convolutional network is extracted local feature maps:

$$h_t^{(c)} = \sigma(W_c * x_t + b_c), \quad t = 1, 2, \dots, T \quad (5)$$

where W_c and b_c denote convolutional filters and biases, $*$ represents convolution, and $\sigma(\cdot)$ is a nonlinear activation function (ReLU).

These features extracted are then fed into a LSTM to extract the temporal dependencies:

$$f_t = \sigma(W_f h_t^{(c)} + U_f h_{t-1} + b_f) \quad (6)$$

$$i_t = \sigma(W_i h_t^{(c)} + U_i h_{t-1} + b_i) \quad (7)$$

$$o_t = \sigma(W_o h_t^{(c)} + U_o h_{t-1} + b_o) \quad (8)$$

$$c_t = f_t \odot c_{t-1} + i_t \odot \tanh(W_c h_t^{(c)} + U_c h_{t-1} + b_c) \quad (9)$$

$$h_t = o_t \odot \tanh(o_t) \quad (10)$$

The last representation that is hidden h_t is fed into a fully connected layer to be classified. This design is specifically applicable to clinical sequential data like ECG or time-series EHR.

2. Ensemble: XGBoost + DNN

The individual consensus is brought together into one assembly of interpretable and gradient boosting qualities of XGBoost and the deep representation of a dense neural network (DNN).

XGBoost Component: With training data (x_i, y_i) , XGBoost tries to optimize an additive tree model:



$$\hat{y}_i = \sum_{k=1}^K f_k(x_i), \quad f_k \in \mathcal{F} \quad (11)$$

Where each f_k is a regression tree and $\mathcal{F}$ denotes the function space of trees. The objective function is:

$$\mathcal{L} = \sum_i l(y_i, \hat{y}_i) + \sum_{k=1}^K \Omega(f_k), \quad \Omega(f) = \gamma T + \frac{1}{2} \lambda ||\omega||^2 \quad (12)$$

with regularization to control complexity.

DNN Component: In addition, a deep feed-forward network acquires non-linear mappings:

$$h^{(l)} = \sigma(W^{(l)}h^{(l-1)} + b^{(l)}), \quad l = 1, 2, \dots, L \quad (13)$$

Where $h^{(0)} = x$.

Fusion: The results of both XGBoost and DNN are then connected and used on a last softmaxing part of the network:

$$\hat{y} = \text{softmax}(W_f \cdot [\hat{y}_{XGB} || h^{(L)}] + b_f) \quad (14)$$

This combination of models leverages structural feature interactions as harbored by XGBoost and high dimensional latent embeddings as held by the DNN.

3. Vision Transformer (ViT)

In contrast to CNNs, the Vision Transformer inputs sequences of patches in an image and uses self-attention to compute global interactions.

Patch Embedding: After dividing an image $x \in \mathbb{R}^{H \times W \times C}$ into N patches, these are flattened and linearly projected:

$$z_0 = [x_p^1 E; x_p^2 E; \dots; x_p^N E] + E_{pos} \quad (15)$$

where E is a learnable projection matrix and E_{pos} denotes positional embeddings.

Transformer Encoder: Each layer processes multi-head self-attention (MHSA) and feed forward blocks:

$$\text{Attention}(Q, K, V) = \text{softmax}\left(\frac{QK^T}{\sqrt{d_k}}\right) V \quad (16)$$

With $Q = zW_Q, K = zW_K, V = zW_V$. Multiple heads are concatenated, followed by:

$$z_l = \text{LayerNorm}(z_{l-1} + \text{MHSA}(z_{l-1})) \quad (17)$$

$$z_l = \text{LayerNorm}(z_l + \text{MLP}(z_l)) \quad (18)$$

The last output is pooled and entered into a classification head:

$$\hat{y} = \text{softmax}(W_{cZL} + b_c) \quad (19)$$

We particularly consider the task of medical imaging where local filters are not satisfactory and contextual representation is essential.



4. Federated Learning (FL)

Federated learning was used to maintain individual privacy whilst also allowing multi-institutional training of models. Local clients train models and only share updating modifications as opposed to data centralization.

For client k with local dataset D_k , the local objective is:

$$\mathcal{L}_k(w) = \frac{1}{|D_k|} \sum_{(x_i, y_i)} l(f_w(x_i), y_i) \quad (20)$$

where f_w is the model parameterized by w . Clients update weights via stochastic gradient descent (SGD):

$$w_k^{t+1} = w^t - \eta \nabla \mathcal{L}_k(w^t) \quad (21)$$

The server is used to aggregate updates by means of weighted averaging (FedAvg):

$$w^{t+1} = \sum_{k=1}^K \frac{|D_k|}{\sum_j |D_j|} w_k^{t+1} \quad (22)$$

This iterative protocol enables global model training without the need for raw data transfer, providing privacy compliance and facilitating collaborative learning fair across distributed health-care institution.

Table 2: Model's architectural Applications and their Strengths

Algorithm	Application	Strengths
CNN + LSTM Hybrid	Time-series EHR analysis	Captures temporal dependencies
Ensemble (XGBoost + DNN)	Laboratory test interpretation	Handles mixed data types
Vision Transformer	Medical image classification	Superior spatial reasoning
Federated Learning	Multi-institutional data collaboration	Preserves privacy

The models used for the algorithm were run first, and thus the Avg. AUC scores for the models are shown in Figure 2.




Figure 2: Performance score for each model



Validation Framework

Three stages of validation were applied to the models:

- i. **Technical verification:** 70/30 split between test and training
- ii. **Clinical validation:** 390 patients retrospectively analyzed
- iii. **Testing in the real world:** ED sepsis detection pilot deployment.

The evaluation matrices for the models are mentioned in Table 3.

Table 3: Evaluation matrices

Metric	Clinical Relevance	Target Threshold
AUC-ROC	Overall diagnostic accuracy	≥ 0.90
Sensitivity	Early detection capability	≥ 0.85
Specificity	False positive reduction	≥ 0.80
F1-score	Balance in imbalanced datasets	≥ 0.75

Implementation and Ethical Considerations

Data management:

- HIPAA-compliant privacy protection
- Federated learning framework for research involving multiple centers

Interpretability of the model:

- CNN explanations using integrated gradients
- Ensemble model LIME plots

Integrating clinical practice:

- Dashboard co-design with RRT nurses
- Contextual notifications to avoid alert fatigue

This approach tackles practical implementation issues while facilitating repeatable, clinically based evaluation of ML systems. By mixing institutional and public datasets, the hybrid strategy guarantees model generalizability without jeopardizing patient privacy.

Experimental Results and Analysis

Across a variety of clinical domains, the incorporation of machine learning (ML) into early disease diagnosis exhibits transformative promise. Quantitative findings demonstrate that algorithmic architecture and disease complexity have a major impact on model performance. The following part discusses the clinical implications, technological difficulties, and potential avenues for future research while synthesizing empirical results from four machine learning architectures tested on five illness categories and backed up by eight analytical tables.

Model Performance Summary Using ROC-AUC Scores




Figure 3: ROC-AUC score for each model

Comparison of ROC curves of the various machine learning models used to diagnose the emerging disease early in healthcare in Figure 3. The plot summarizes the performance of four candidate models, a CNN + LSTM Hybrid Ensemble, an XGBoost combined with Deep Neural Network (DNN), a Vision Transformer, and a Federated Learning framework implemented by the classification performance. The ROC curves give an overall perspective of this trade-off between sensitivity (True Positive Rate) and specificity (1-False Positive Rate) at translating different decision thresholds.

The findings demonstrate that the Vision Transformer produce the best diagnostic result of an AUC of 0.96, assigning a steep triangular profile with a strong inclination sharply rising to the top-left corner, which renders highly discriminative model. The CNN + LSTM Hybrid Ensemble is slightly behind with an AUC of 0.93 and can be seen as a strong sequential/spatial feature learning model. The Ensemble (XGBoost + DNN) model achieves an AUC of 0.91 that is steady yet less steep than the hybrid networks. Compared to the discriminative power of 0.89, the Federated Learning framework has potential in privacy-preserving collaborative training, but not on a too high scale.

Model Performance Summary

Table 4: AUC score of the models

Model	Cardiovascular	Diabetes	Cancer	Alzheimer	Sepsis
CNN + LSTM Hybrid	0.899	0.87	0.853	0.874	0.93
Ensemble (XGBoost + DNN)	0.952	0.929	0.955	0.866	0.936
Vision Transformer	0.976	0.97	0.901	0.921	0.95
Federated Learning	0.945	0.962	0.892	0.866	0.914

By using its self-attention mechanisms to recognize spatial patterns in imaging data, the Vision Transformer was able to attain superior AUC scores in the diagnosis of diabetes (0.970) and cardiovascular disease (0.976). For cancer diagnosis, however, where tumor heterogeneity necessitated more specific structures, its efficacy declined to 0.901 AUC.




Figure 4: ROC curves of four machine learning models for early disease diagnosis across five major diseases: cardiovascular disease, diabetes, cancer, Alzheimer's disease, and sepsis.

The ROC curves in Figure 4 are used to demonstrate the discriminative abilities of each model based on respective disease. The Vision Transformer shows consistently and significantly the best performance measure, AUC, across the majority of conditions, especially in cardiovascular disease (AUC = 0.976), diabetes (0.970), Alzheimer (0.921), and sepsis (0.950) indicating its capability to model the global complexity compelling in clinical data. The Ensemble model (XGBoost + DNN) performed equally well in both tasks (AUC = 0.955 in cancer and 0.936 in sepsis), which hints at a benefit of combining tree-based and deep learning representations. The CNN + LSTM Hybrid model shows promising results in the choice of sepsis (AUC = 0.930), but its capabilities allow using both sequential and spatial features, whereas Federated Learning demonstrates competitive performance in diabetes (0.962) and cardiovascular disease (0.945) and could be used in privacy-preserving collaborative diagnostics.

In general, the curves have the shape of a triangle, reflecting on a high sensitivity under low false positive rates, which is important in the context of early disease identification. This detailed comparison reveals that transformer-based and ensemble have the best prediction ability when compared to other methods, however, federated learning is appropriate when a research topic concerns performance and data privacy.

Sensitivity-Specificity Tradeoffs

For different diseases, different models were proven accurate. So they were compared to each other. Figures 5 to 8 are the model comparisons between different models.




Figure 5: Sensitivity-specificity for cardiovascular disease.




Figure 6: Sensitivity-specificity for diabetes.




Figure 7: Sensitivity-specificity for Alzheimer's.




Figure 8: Sensitivity-specificity for Sepsis.

The best sensitivity for detecting sepsis (0.878) was shown by federated learning models, which is essential for reducing false negatives in situations where time is of the essence. On the other hand, the Vision Transformer reduced needless interventions by maintaining remarkable specificity (0.938) in cardiovascular diagnosis.

Computational Efficiency

The models were tasted at different time laps. Some took longer to run than the others. Table 5 shows the runtime summary of the models.

Table 5: Computational efficiency matrices

Model	Training Time (h)	Inference Latency (ms)	Memory Usage (GB)
CNN + LSTM Hybrid	14.2	120	8.5
Vision Transformer	22.8	85	12.3
Federated Learning	34.1	210	6.2

The Vision Transformer presented difficulties for real-time clinical adoption because it took 64% longer to train than CNN-based models, despite its high diagnostic accuracy. The distributed design of federated learning introduced latency tradeoffs while minimizing memory use (6.2GB).




Figure 9: Trade-off between Training Time and Inference Latency for different machine learning models

The slope plot in Figure 9 visualizes the relative computational costs of three models, CNN + LSTM Hybrid, Vision Transformer and Federated Learning. The blue line shows the Training Time, whereas the orange line is Inference Latency.

Based on the figure, it is evident that the CNN + LSTM Hybrid model has minimum training time (approximately 42 percent of the maximum) and inference latency of moderate level (57 percent of the maximum). As such, it is more appropriate to use the model to develop training quickly. The Vision Transformer has a more significant training time (~67 %), and lower inference latency (~40 %) which suggests fast deployment once trained. Protecting Privacy averages the greatest share in time, and Inference latency is greater as well (~100%) due to the constituent costs of decentralized training and privacy-preserving operations.

This visualization shows how models may have different trade-offs with regard to training efficiencies and speed of deployment, which can be used to explicitly guide the choice of models when clinical or operational priorities differ.

Disease-specific observation

Table 6: Test results for different models for Alzheimer's disease.

Model	AUC	Sensitivity	Specificity
Vision Transformer	0.921	0.821	0.91
Federated Learning	0.866	0.907	0.902
Ensemble	0.866	0.874	0.757

By balancing amyloid PET scan analysis with cognitive test data, the Ensemble model for Alzheimer's disease obtained the greatest F1-score (0.882), while Vision Transformer's 0.910 specificity decreased false positives in patients in the early stages of the disease. So it was determined that the sample for research would be collected using an ensemble model for Alzheimer's. Figure 10 shows a comparative graph for F1 scores after validation.




Figure 10: F1 score for different models for Alzheimer's disease.

Table 7: Test results for different models for Sepsis

Model	Precision	Recall	Accuracy
Vision Transformer	0.892	0.83	0.906
Federated Learning	0.763	0.878	0.816
CNN + LSTM Hybrid	0.801	0.821	0.868

By combining sequential vital signs with laboratory trends, Vision Transformer's 0.950 AUC beat other models in sepsis prediction; however, its 0.830 recall lagged behind Federated Learning's 0.878, indicating significant disparities in detection time. Figure 12 shows the F1 score for models for Sepsis.

Comparison of Precision, Recall, and Accuracy Across Models




Figure 11: Comparison of Precision, Recall, and Accuracy for three machine learning models: Vision Transformer, Federated Learning, and CNN + LSTM Hybrid

The radar plot in Figure 11 also indicates the relative strengths of each model in prediction of early disease. The Vision Transformer constantly brings the most impressive results in all three metrics, where Precision is 0.892, Recall is 0.830 and Accuracy is 0.906, showing overall well-balanced and stable performance. The CNN + LSTM Hybrid model shows medium results, with Precision of 0.801, Recall being 0.821 and Accuracy as 0.868 as it can model both sequential and spatial data. A relatively higher recall (0.878) of Federated Learning than its precision (0.763) and accuracy (0.816) indicates that it is highly sensitive in identifying the locations of the positive cases, an aspect important in privacy-preserving distributed healthcare.



Comprehensively, the plot shows that the Vision Transformer performs better in terms of overall predictiveness, whereas the CNN + LSTM Hybrid and Federated Learning models, although less accurate overall, are better suited to meet certain clinical aims due to their sensitivity/precision trade- off pattern. The radar form allows comparing the three metrics in a single and holistic view and thereby directly highlights differences in model performances.




Figure 12: F1 score for different models for Sepsis.

Implementation Challenges

The greatest hurdle, according to clinicians, was model interpretability (4.7 severity score), especially for Vision Transformer's attention maps, which needed specific training to be used effectively in clinical settings.

Table 8: Clinical deployment barriers.

Challenge	Mitigation Strategy
Model interpretability	Integrated Gradients
Data heterogeneity	Federated normalization
Alert fatigue	Context-aware triggering

Frequency and Severity of Challenges in ML-Based Healthcare




Figure 13: Frequency and severity of challenges in ML-based healthcare applications

The radial plot in Figure 13 illustrates three major challenges that will be met in machine learning in healthcare Model interpretability, Data heterogeneity, and Alert fatigue. The length



of each segment protruding the center corresponds to the frequency of the challenge, measured as the percentage of respondents who report it, and the value that is annotated corresponds to its severity measured between 1 and 5.

It can be observed that the Model interpretability is the most often and the most serious challenge (89%, severity 4.7), followed by Data heterogeneity (76%, severity 4.2) and Alert fatigue (68%, severity 3.9). Such dual representation can point out not only what challenges are typical but also their relative severity, giving actionable insight into prioritizing research and development of clinical machine learning systems.

Table 9: Ethical challenges

Issue	Occurrence Rate	Impact	Resolution Rate
Dataset bias	32%	Reduced generalizability	78%
Privacy leaks	11%	Regulatory non-compliance	92%
Algorithmic fairness	24%	Disparate outcomes	65%

Although there were only 11% of privacy leaks, dataset bias impacted over one-third of models, especially in skin cancer detection when Fitzpatrick scale diversity was inadequate.

Integrated Discussion

The field of clinical diagnostics is seeing rapid advancements thanks to machine learning models, but their practical application depends on factors other than performance indicators. This section uses comparative studies of architectures like as Vision Transformers, CNN + LSTM hybrids, and Federated Learning systems to examine the complex relationship between clinical utility and diagnostic accuracy. Although good AUC scores demonstrate the promise of algorithms, their practicality is significantly shaped by aspects including inference latency, training time, generalizability across care settings, and ethical constraints. By breaking down these factors, we highlight how crucial it is to strike a balance between technological excellence and real-world implementation limitations in order to guarantee that advances result in observable patient benefits.

Clinical Utility vs. Diagnostic Accuracy: Technical superiority is demonstrated by the Vision Transformer's 0.976 AUC in cardiovascular diagnosis (Table 3), but hospital adoption may be constrained by its 22.8-hour training period (Table 5). Federated Learning, on the other hand, is better for multi-institutional collaborations because of its HIPAA-compliant architecture, which balances out its modest AUC scores (0.866-0.914).

Recognition of Temporal Patterns: By processing sequential EHR data, CNN + LSTM Hybrid models performed exceptionally well in sepsis prediction (0.930 AUC); nevertheless, their 120ms inference latency (Table 5) may cause critical care treatments to be delayed. This is in contrast to Vision Transformer, which uses parallelized attention computations to reach a latency of 85 ms.

Gaps in Real-World Validation: Prospective trials showed 18% performance degradation when applied to community hospital data, although reaching 0.921 AUC in Alzheimer's detection (Table 6). This highlights the necessity of varied training cohorts. Similarly, in ambulatory care settings, the missing patient histories caused the Ensemble model's 0.882 F1-score for Alzheimer's to decline to 0.791.

Framework for Ethical Implementation: Through differential privacy protections, the Federated Learning architecture decreased privacy leak incidences to 11% (Table 9). However, in comparison to centralized models, it resulted in a 37% increase in compute costs. Institution-



specific risk evaluations are necessary to balance these tradeoffs, especially for vulnerable populations.

These findings support machine learning's ability to improve early disease detection while emphasizing its context-dependent drawbacks. Different therapeutic needs are addressed by the imaging capabilities of the Vision Transformer, the temporal analysis of CNN + LSTM, and the privacy preservation of Federated Learning. To convert algorithmic performance into quantifiable patient outcomes, future research must give top priority to computational optimization, real-world validation, and ethical governance frameworks.

Further from this research, the future of ML in early disease diagnosis can be easily described as:

The Future of Machine Learning in Early Disease Diagnosis

In the field of early disease diagnosis, machine learning (ML) is at the front of a technological revolution in healthcare. Through the utilization of extensive and varied datasets, such as genomic sequences, medical imaging, electronic health records, and physiological signals, machine learning algorithms are able to detect minute trends and forecast the beginning of diseases with previously unheard-of speed and precision. By facilitating earlier interventions, more individualized therapies, and eventually better patient outcomes, this skill has the potential to revolutionize therapeutic practice. The use of machine learning (ML) in diagnostic procedures is set to become not just beneficial but also necessary as the amount and complexity of healthcare data continue to increase. Several significant themes define the future of machine learning in early disease diagnosis:

1. **Multimodal Data Integration:** In order to present a comprehensive picture of patient health, next-generation machine learning models are becoming more and more adept at combining data from many sources, including imaging, genomics, clinical notes, and wearable technology. Especially for complicated or multifactorial diseases like cancer, cardiovascular ailments, and neurological conditions, this integration improves diagnostic precision.
2. **Real-Time and Remote Diagnostics:** ML-powered diagnostic tools may now operate in real-time and outside of conventional clinical settings due to developments in edge computing and telemedicine. Disparities in healthcare access can be decreased by using portable devices and smartphone applications with trained machine learning models to enable early identification in distant or resource-constrained settings.
3. **Personalized and Predictive Medicine:** Machine learning models are being used more and more to predict the course of diseases, stratify patients based on risk, and customize screening or preventative measures to each patient's unique profile. Early and more focused therapies are made possible by this change from reactive to proactive care, which may lessen the severity of the illness and save long-term medical expenses.
4. **Explainable and Trustworthy AI:** More transparency and interpretability are being incorporated into the architecture of future machine learning systems in order to promote clinician trust and assist with regulatory compliance. By demystifying model predictions, explainable AI (XAI) tools assist medical professionals comprehend and validate diagnostic recommendations.
5. **Collaborative and Federated Learning:** Without jeopardizing patient confidentiality, privacy-preserving techniques like federated learning enable ML models to be trained on decentralized data across institutions. While resolving the moral and legal issues around data sharing, this cooperative paradigm spurs innovation.



6. **Difficulties and Considerations:** Even with these developments, there are still a number of difficulties. To prevent biases that can jeopardize diagnostic equity, it is imperative to ensure data representativeness and quality. Confirming the generalizability of the paradigm requires rigorous evaluation in many clinical situations. Furthermore, rigorous workflow planning, user training, and continuous safety and effectiveness monitoring are necessary when incorporating ML techniques into current healthcare infrastructures.

ML has a bright and revolutionary future in early disease diagnosis. ML will allow for earlier, more precise, and more individualized illness identification as algorithms advance and datasets grow in size, radically changing the field of preventative medicine. To address issues with bias, transparency, and ethical use, however, interdisciplinary cooperation between clinicians, data scientists, and legislators is necessary to realize this promise. By overcoming these obstacles, machine learning (ML) can realize its potential to transform early disease detection, enhancing patient outcomes for each person and promoting global public health.

Conclusion

The implementation of machine learning (ML) into the field of early disease diagnosis perpetuates a new age of medicine where diagnostic performance can be universally augmented through applications of the technology, leading to faster action, better patient outcomes and vastly reduced scope of deficiency. This paper shows that the use of advanced ML models, including convolutional neural networks, recurrent neural networks, Vision Transformers, and federated learning frameworks can produce much better results than the traditional diagnostic methods, with AUC scores ranging between 0.94 and 0.96 and sensitivity rates up to 0.878 in cases of diabetes, cancer, cardiovascular disease, Alzheimer, and sepsis. This should allow proactive and personalized care delivery, minimizing diagnosis errors and health disparities, and maximizing resource distribution.

Although this is a great accomplishment, there are still great challenges. The limited diversity of real-world complexity and a dataset may not support model generalizability, which threatens to promote healthcare disparities. The intricacy of many ML designs engulfs regulatory approval and achieves clinician credence, which inheres the significance of explainable AI systems. Requirements of interoperability with the rest of the health IT systems, usable interfaces, and thorough training of medical personnel are necessitated by the necessity to integrate with clinical workflows. Ethical and regulatory considerations may be crucial, especially with regard to patient privacy, data privacy, and ongoing monitoring of models, to make sure that they are responsible on their part in the deployment.

Future studies that work to develop interpretable, generalizable and bias-mitigated models through interdisciplinary collaboration between clinicians, data scientists and policymakers are vital towards fulfilling the potential of ML. Upwardly scaled, multi-Centre prospective study is vital to confirm real world effectiveness and safety. This will encourage reliable systems of exchanging data and lead to innovation without jeopardizing privacy. Due to these difficulties, the implementation of ML in the field of healthcare can disrupt the current paradigm, providing an equitable, efficient, and sustainable boost in global health outcomes and turning global healthcare into a proactive process focused on serving the needs of an individual patient.



Reference

- [1] A. Nayyar, L. Gadhavi, and N. Zaman, "Machine learning in healthcare: review, opportunities and challenges," *Machine Learning and the Internet of Medical Things in Healthcare*, pp. 23–45, Jan. 2021, doi: 10.1016/B978-0-12-821229-5.00011-2.
- [2] S. Patil *et al.*, "Artificial Intelligence in the Diagnosis of Oral Diseases: Applications and Pitfalls," *Diagnostics 2022, Vol. 12, Page 1029*, vol. 12, no. 5, p. 1029, Apr. 2022, doi: 10.3390/DIAGNOSTICS12051029.
- [3] M. M. Ahsan, S. A. Luna, and Z. Siddique, "Machine-Learning-Based Disease Diagnosis: A Comprehensive Review," *Healthcare 2022, Vol. 10, Page 541*, vol. 10, no. 3, p. 541, Mar. 2022, doi: 10.3390/HEALTHCARE10030541.
- [4] P. Usán Supervía *et al.*, "Teaching, Learning and Assessing Anatomy with Artificial Intelligence: The Road to a Better Future," *International Journal of Environmental Research and Public Health 2022, Vol. 19, Page 14209*, vol. 19, no. 21, p. 14209, Oct. 2022, doi: 10.3390/IJERPH192114209.
- [5] V. Chang, V. R. Bhavani, A. Q. Xu, and M. A. Hossain, "An artificial intelligence model for heart disease detection using machine learning algorithms," *Healthcare Analytics*, vol. 2, p. 100016, Nov. 2022, doi: 10.1016/J.HEALTH.2022.100016.
- [6] T. R. Ramesh, U. K. Lilhore, M. Poongodi, S. Simaiya, A. Kaur, and M. Hamdi, "PREDICTIVE ANALYSIS OF HEART DISEASES WITH MACHINE LEARNING APPROACHES," *Malaysian Journal of Computer Science*, vol. 2022, no. Special Issue 1, pp. 132–148, Mar. 2022, doi: 10.22452/MJCS.SP2022NO1.10.
- [7] B. Ihnaini *et al.*, "A Smart Healthcare Recommendation System for Multidisciplinary Diabetes Patients with Data Fusion Based on Deep Ensemble Learning," *Comput Intell Neurosci*, vol. 2021, no. 1, p. 4243700, Jan. 2021, doi: 10.1155/2021/4243700.
- [8] J. Ramesh, R. Aburukba, and A. Sagahyroon, "A remote healthcare monitoring framework for diabetes prediction using machine learning," *Healthc Technol Lett*, vol. 8, no. 3, pp. 45–57, Jun. 2021, doi: 10.1049/HTL2.12010.
- [9] K. Das *et al.*, "Machine Learning and Its Application in Skin Cancer," *International Journal of Environmental Research and Public Health 2021, Vol. 18, Page 13409*, vol. 18, no. 24, p. 13409, Dec. 2021, doi: 10.3390/IJERPH182413409.
- [10] N. Yamanakkanavar, J. Y. Choi, and B. Lee, "MRI Segmentation and Classification of Human Brain Using Deep Learning for Diagnosis of Alzheimer's Disease: A Survey," *Sensors 2020, Vol. 20, Page 3243*, vol. 20, no. 11, p. 3243, Jun. 2020, doi: 10.3390/S20113243.
- [11] A. V. L. N. Sujith, G. S. Sajja, V. Mahalakshmi, S. Nuhmani, and B. Prasanalakshmi, "Systematic review of smart health monitoring using deep learning and Artificial intelligence," *Neuroscience Informatics*, vol. 2, no. 3, p. 100028, Sep. 2022, doi: 10.1016/J.NEURI.2021.100028.
- [12] E. E. Lee *et al.*, "Artificial Intelligence for Mental Health Care: Clinical Applications, Barriers, Facilitators, and Artificial Wisdom," *Biol Psychiatry Cogn Neurosci Neuroimaging*, vol. 6, no. 9, pp. 856–864, Sep. 2021, doi: 10.1016/J.BPSC.2021.02.001.



- [13] J. Xu *et al.*, “Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives,” *Hum Genet*, vol. 138, no. 2, pp. 109–124, Feb. 2019, doi: 10.1007/S00439-019-01970-5/TABLES/1.
- [14] Y. Kumar, S. Gupta, R. Singla, and Y. C. Hu, “A Systematic Review of Artificial Intelligence Techniques in Cancer Prediction and Diagnosis,” *Archives of Computational Methods in Engineering*, vol. 29, no. 4, pp. 2043–2070, Jun. 2022, doi: 10.1007/S11831-021-09648-W/METRICS.
- [15] A. Rehman, S. Abbas, M. A. Khan, T. M. Ghazal, K. M. Adnan, and A. Mosavi, “A secure healthcare 5.0 system based on blockchain technology entangled with federated learning technique,” *Comput Biol Med*, vol. 150, p. 106019, Nov. 2022, doi: 10.1016/J.COMPBIOMED.2022.106019.
- [16] K. A. Tran, O. Kondrashova, A. Bradley, E. D. Williams, J. V Pearson, and N. Waddell, “Deep learning in cancer diagnosis, prognosis and treatment selection”, doi: 10.1186/s13073-021-00968-x.
- [17] İ. D. Kocakoç, “The Role of Artificial Intelligence in Health Care,” *Accounting, Finance, Sustainability, Governance and Fraud*, pp. 189–206, 2022, doi: 10.1007/978-981-16-8997-0_11.
- [18] S. Uddin, A. Khan, M. E. Hossain, and M. A. Moni, “Comparing different supervised machine learning algorithms for disease prediction,” *BMC Med Inform Decis Mak*, vol. 19, no. 1, pp. 1–16, Dec. 2019, doi: 10.1186/S12911-019-1004-8/FIGURES/12.
- [19] H. Habebh and S. Gohel, “Machine Learning in Healthcare,” *Curr Genomics*, vol. 22, no. 4, pp. 291–300, Jul. 2021, doi: 10.2174/1389202922666210705124359/CITE/REFWORKS.
- [20] S. Mall, A. Srivastava, B. D. Mazumdar, M. Mishra, S. L. Bangare, and A. Deepak, “Implementation of machine learning techniques for disease diagnosis,” *Mater Today Proc*, vol. 51, pp. 2198–2201, Jan. 2022, doi: 10.1016/J.MATPR.2021.11.274.
- [21] R. Vincent *et al.*, “IoT-Cloud-Based Smart Healthcare Monitoring System for Heart Disease Prediction via Deep Learning,” *Electronics 2022, Vol. 11, Page 2292*, vol. 11, no. 15, p. 2292, Jul. 2022, doi: 10.3390/ELECTRONICS11152292.
- [22] S. S. Kute, A. V. Shreyas Madhav, S. Kumari, and S. U. Aswathy, “Machine Learning–Based Disease Diagnosis and Prediction for E-Healthcare System,” *Advanced Analytics and Deep Learning Models*, pp. 127–147, May 2022, doi: 10.1002/9781119792437.CH6.
- [23] M. Javaid, A. Haleem, R. Pratap Singh, R. Suman, and S. Rab, “Significance of machine learning in healthcare: Features, pillars and applications,” *International Journal of Intelligent Networks*, vol. 3, pp. 58–73, Jan. 2022, doi: 10.1016/J.IJIN.2022.05.002.
- [24] M. (Moazzam) Siddiq, “Use of Machine Learning to Predict Patient Developing A Disease or Condition for Early Diagnose,” *International Journal of Multidisciplinary Sciences and Arts*, vol. 1, no. 1, p. 591841, Jun. 2022, doi: 10.47709/IJMDSA.V1I1.2271.
- [25] N. G. Maity and S. Das, “Machine learning for improved diagnosis and prognosis in healthcare,” *IEEE Aerospace Conference Proceedings*, Jun. 2017, doi: 10.1109/AERO.2017.7943950.



- [26] M. J. Iqbal *et al.*, “Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future,” *Cancer Cell Int*, vol. 21, no. 1, pp. 1–11, Dec. 2021, doi: 10.1186/S12935-021-01981-1/FIGURES/4.
- [27] T. J. Saleem and M. A. Chishti, “Exploring the Applications of Machine Learning in Healthcare,” *International Journal of Sensors, Wireless Communications and Control*, vol. 10, no. 4, pp. 458–472, Dec. 2019, doi: 10.2174/2210327910666191220103417/CITE/REFWORKS.
- [28] P. Singh, N. Singh, K. K. Singh, and A. Singh, “Diagnosing of disease using machine learning,” *Machine Learning and the Internet of Medical Things in Healthcare*, pp. 89–111, Jan. 2021, doi: 10.1016/B978-0-12-821229-5.00003-3.
- [29] F. Jiang *et al.*, “Artificial intelligence in healthcare: past, present and future,” *Stroke Vasc Neurol*, vol. 2, no. 4, pp. 230–243, Dec. 2017, doi: 10.1136/SVN-2017-000101.
- [30] L. D. Jones, D. Golan, S. A. Hanna, and M. Ramachandran, “Artificial intelligence, machine learning and the evolution of healthcare: A bright future or cause for concern?,” *Bone Joint Res*, vol. 7, no. 3, pp. 223–225, Mar. 2018, doi: 10.1302/2046-3758.73.BJR-2017-0147.R1/LETTERTOEDITOR.
- [31] T. A. A. Abdullah, M. S. M. Zahid, and W. Ali, “A Review of Interpretable ML in Healthcare: Taxonomy, Applications, Challenges, and Future Directions,” *Symmetry 2021, Vol. 13, Page 2439*, vol. 13, no. 12, p. 2439, Dec. 2021, doi: 10.3390/SYM13122439.
- [32] K. Kumar, K. Chaudhury, and S. L. Tripathi, “Future of Machine Learning (ML) and Deep Learning (DL) in Healthcare Monitoring System,” *Machine Learning Algorithms for Signal and Image Processing*, pp. 293–313, Nov. 2022, doi: 10.1002/9781119861850.CH17.
- [33] F. Mulisa, “When Does a Researcher Choose a Quantitative, Qualitative, or Mixed Research Approach?,” *Interchange*, vol. 53, no. 1, pp. 113–131, Mar. 2022, doi: 10.1007/S10780-021-09447-Z/METRICS.
- [34] Z. M. Yaseen, “An insight into machine learning models era in simulating soil, water bodies and adsorption heavy metals: Review, challenges and solutions,” *Chemosphere*, vol. 277, p. 130126, Aug. 2021, doi: 10.1016/J.CHEMOSPHERE.2021.130126.
- [35] A. Zhang, L. Xing, J. Zou, and J. C. Wu, “Shifting machine learning for healthcare from development to deployment and from models to data,” *Nat Biomed Eng*, vol. 6, no. 12, pp. 1330–1345, Dec. 2022, doi: 10.1038/S41551-022-00898-Y;SUBJMETA.
- [36] P. G. Asteris, A. D. Skentou, A. Bardhan, P. Samui, and K. Pilakoutas, “Predicting concrete compressive strength using hybrid ensembling of surrogate machine learning models,” *Cem Concr Res*, vol. 145, p. 106449, Jul. 2021, doi: 10.1016/J.CEMCONRES.2021.106449.